1. Home
  2. BBIO vs FE Comparison

BBIO vs FE Comparison

Compare BBIO & FE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
  • FE
  • Stock Information
  • Founded
  • BBIO 2015
  • FE 1996
  • Country
  • BBIO United States
  • FE United States
  • Employees
  • BBIO N/A
  • FE N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • FE Electric Utilities: Central
  • Sector
  • BBIO Health Care
  • FE Utilities
  • Exchange
  • BBIO Nasdaq
  • FE Nasdaq
  • Market Cap
  • BBIO 8.0B
  • FE N/A
  • IPO Year
  • BBIO 2019
  • FE N/A
  • Fundamental
  • Price
  • BBIO $46.47
  • FE $40.52
  • Analyst Decision
  • BBIO Strong Buy
  • FE Buy
  • Analyst Count
  • BBIO 14
  • FE 15
  • Target Price
  • BBIO $60.21
  • FE $46.15
  • AVG Volume (30 Days)
  • BBIO 3.3M
  • FE 4.5M
  • Earning Date
  • BBIO 07-31-2025
  • FE 07-30-2025
  • Dividend Yield
  • BBIO N/A
  • FE 4.39%
  • EPS Growth
  • BBIO N/A
  • FE 1.45
  • EPS
  • BBIO N/A
  • FE 1.88
  • Revenue
  • BBIO $127,415,000.00
  • FE $13,764,000,000.00
  • Revenue This Year
  • BBIO $107.34
  • FE $9.20
  • Revenue Next Year
  • BBIO $49.48
  • FE $3.82
  • P/E Ratio
  • BBIO N/A
  • FE $21.54
  • Revenue Growth
  • BBIO N/A
  • FE 8.03
  • 52 Week Low
  • BBIO $21.72
  • FE $37.58
  • 52 Week High
  • BBIO $46.80
  • FE $44.97
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 71.64
  • FE 50.10
  • Support Level
  • BBIO $41.80
  • FE $39.34
  • Resistance Level
  • BBIO $46.80
  • FE $40.59
  • Average True Range (ATR)
  • BBIO 1.44
  • FE 0.53
  • MACD
  • BBIO 0.09
  • FE 0.11
  • Stochastic Oscillator
  • BBIO 94.00
  • FE 76.08

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: